Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas

Area of Science:

• Oncology
• Cancer Biology
• Stem Cell Therapy

Background:

• Sarcomas are aggressive pediatric and young adult cancers with high relapse and mortality rates.
• Mesenchymal stromal/stem cells (MSC) are implicated in sarcoma development and microenvironment support.
• Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potent inducer of apoptosis.

Purpose of the Study:

• To investigate the therapeutic potential of genetically modified MSC to deliver TRAIL for sarcoma treatment.
• To evaluate the efficacy of MSC-TRAIL in inducing apoptosis and inhibiting tumor growth in various sarcoma types.
• To assess the antiangiogenic effects of MSC-TRAIL in an in vivo sarcoma model.

Main Methods:

• Gene modification of MSC to express TRAIL.
• In vitro co-culture experiments with osteosarcoma, rhabdomyosarcoma, and Ewing's Sarcoma (ES) cell lines.
• In vivo xenotransplantation model using ES to assess tumor apoptosis, size, and angiogenesis.

Main Results:

• MSC-TRAIL significantly induced apoptosis in all tested sarcoma cell lines.
• Sarcoma cell death was mediated by caspase-8 activation.
• In vivo, MSC-TRAIL demonstrated significant tumor apoptosis and antiangiogenic effects in ES xenografts.
• MSC-TRAIL persisted within the tumor stroma, indicating effective delivery.

Conclusions:

• Genetically modified MSC expressing TRAIL represent a promising therapeutic strategy for sarcomas.
• MSC-TRAIL exhibits dual mechanisms of action: direct tumor cell killing and antiangiogenesis.
• This approach offers novel therapeutic opportunities for challenging sarcoma histotypes.